

Partner, Wilmington

Mergers and Acquisitions; Private Equity



T: 302.651.3250
faiz.ahmad@skadden.com

Education

J.D., Washington & Lee University
School of Law
B.A., University of Maryland

Bar Admissions

Delaware

Faiz Ahmad is the head of Skadden's Wilmington office. He focuses on mergers and acquisitions, private equity transactions, corporate and securities matters, and Delaware corporate and alternative entity law.

Mr. Ahmad represents public and private clients and private equity sponsors in a variety of U.S. and cross-border corporate transactions, including mergers, acquisitions, dispositions, investments, joint ventures, restructurings and REIT matters. He works extensively on the structuring and formation of limited liability companies and other alternative entities for use in private equity transactions, joint ventures and other complex business arrangements.

Mr. Ahmad serves as chair of the Wilmington office's Hiring Committee and is a former member of Skadden's governing body, the Policy Committee.

Notable representations include:

- Vertex Pharmaceuticals in its:
 - \$4.9 billion acquisition of Alpine Immune Sciences
 - \$320 million acquisition of ViaCyte
 - \$950 million acquisition of Semma Therapeutics, Inc.
- MorphoSys AG in its:
 - \$2.9 billion sale to Novartis and simultaneous disposition of Monjuvi to Incyte
 - \$1.7 billion acquisition of Constellation Pharmaceuticals and its related financing from Royalty Pharma totaling over \$2 billion
- BELLUS Health in its \$2 billion sale to GSK
- ABP Acquisition LLC in its acquisition of AlerisLife Inc.
- Alcon in its:
 - acquisition of LumiThera Inc.
 - \$753 million acquisition of Aerie Pharmaceuticals
 - \$355 million acquisition of the U.S. commercialization rights to Simbrinza from Novartis
- Antares Pharma in its \$1 billion sale to Halozyme Therapeutics
- Banner Life Sciences, LLC in its acquisition by Cycle Pharmaceuticals, Inc.
- Corporation Service Company in its \$2 billion public offer for Intertrust Group
- ESSA Pharma Inc. in its acquisition by XenoTherapeutics, Inc.
- the special committee of the board of directors of R1 RCM Inc. in its acquisition by investment funds affiliated with TowerBrook Capital Partners, L.P. and Clayton, Dubilier & Rice, LLC
- Rithm Capital in its \$1.675 billion acquisition of Caliber Home Loans, Inc.
- The RMR Group, a \$43 billion alternative asset management company, and its public and private managed clients with respect to corporate transactions, including its acquisition of MPC Partnership Holdings, LLC (d/b/a CARROLL), and general corporate and securities matters

Faiz Ahmad

Continued

- RMR Mortgage Trust in its all-stock merger with Tremont Mortgage Trust and related transactions
- JLL Partners, a leading private equity sponsor, in a number of transactions, including its:
 - acquisition of Jonathan Engineered Solutions, a designer and manufacturer of enclosures for defense, commercial aerospace and specialty industrial end markets and three subsequent add-on transactions
 - acquisition of Modus Create, a specialized software services firm
 - acquisition of Secretariat Advisors, a specialty consulting firm, and four subsequent add-on transactions
 - investment in Breakwater Solutions, a consulting, software and managed services company addressing information governance and data technology
 - sale of Loar Group, a diversified manufacturer and supplier of aerospace and defense components
 - acquisition of Xact Data Discovery, a provider of litigation support services and electronic discovery, data management and managed review services
- American Dental Partners, a dental practice management company, in its sale to Heartland Dental
- Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company, in its sale to Menarini Group for \$677 million
- Sonesta International Hotels in the restructuring of its management agreements with Service Properties Trust and in a recapitalization
- The Blommer Chocolate Company in its sale to Fuji Oil
- Carbonite in its:
 - sale to OpenText for \$1.42 billion
 - \$618.5 million acquisition of Webroot
- Forrester Research in its \$245 million acquisition of Sirius Decisions
- Modular Space Holdings in its \$1.2 billion sale to WillScot Corporation
- Patheon N.V. in its initial public offering and subsequent \$7.2 billion sale to Thermo Fisher Scientific
- DPx Holdings in its acquisitions of Patheon Inc. and the concurrent contribution of Royal DSM's pharmaceutical business, and the subsequent acquisitions of three pharmaceutical services businesses

- BioClinica, a global provider of clinical trial services and technology to contract research organizations, in several acquisitions and its \$1.4 billion sale to Cinven
- Windstream Holdings in its \$1.1 billion acquisition of EarthLink Holdings
- 2U, Inc. in its acquisition of GetSmarter
- MFP Partners, LP in its minority investment in First Security Group, Inc., a publicly traded bank holding company, and in its investment in Cache, Inc., a nationwide, mall-based specialty retailer of sportswear
- Drogaria Onofre Ltd., Brazil's eighth-largest drugstore chain, in its sale to CVS Caremark Corporation
- TOMS Shoes in its sale of a 50% interest in TOMS to Bain Capital, and related transactions
- Sequential Brands Group in its acquisition of Heelys by virtue of a negotiated topping bid to an announced transaction
- Wilmington Trust in its merger with M&T Bank Corporation

Mr. Ahmad is a member of the Corporation Law Council and its Alternative Entity Subcommittee. He has served in various leadership positions with the South Asian Bar Association of North America and as president of its Delaware chapter. He also was a fellow of the Leadership Council on Legal Diversity.

Mr. Ahmad has been recognized in *Chambers USA, The Best Lawyers in America* and *IFLR1000*, as well as named one of *Lawdragon's 500 Leading Dealmakers in America* and a *Delaware Lawyer on the Fast Track* by *The Delaware Law Weekly*. He has also been repeatedly selected to *Delaware Business Times' Delaware 222* list, recognizing "the state's most important, and up-and-coming, leaders across a variety of industries."

From 2009-10, he served as counsel to Acumen Fund, a global patient capital impact investing fund focused on early-stage enterprises that provide low-income consumers with access to health care, water, housing, alternative energy or agricultural inputs.